PB203 / Panolos Biosci, Sichuan Kelun Pharma - LARVOL DELTA

An innovative multi-specific Fc fusion protein simultaneously targeting PD-L1, VEGF-A, and PLGF for pancreatic cancer treatment via reshaping the tumor microenvironment (AACR 2025) - "In an orthotopic pancreatic cancer model using humanized mice treated with gemcitabine, PB203 achieved significant anti-tumor efficacy, including cases of complete regression. PB203 demonstrated substantial anti-tumor activity in an orthotopic pancreatic cancer model featuring an immunosuppressive TME, closely mirroring patient conditions. Its ability to inhibit CAFs and reduce fibrosis within the TME, likely driven by PLGF blockade, represents a unique mechanism of action. These findings suggest that beyond emerging PD-(L)1/VEGF-A bi-specific strategies, triple blockade of PD-(L)1, VEGF-A, and PLGF with PB203 could offer a novel therapeutic option for highly desmoplastic and hard-to-treat cancers like pancreatic cancer."

Biomarker • Tumor microenvironment • Oncology • Pancreatic Cancer • Solid Tumor • CAFs

Panoros Biosciences Announces Next-Generation Anticancer Drug ’PB203’ Results at AACR 2025 [Google translation] (BioTimes) - "Panoros Biosciences...announced on the 21st that it will present the preclinical research results of its next-generation anticancer drug candidate 'PB203' at the '2025 American Association for Cancer Research' (AACR 2025), which will be held in Chicago, USA from the 25th to the 30th....In this study, Panoros demonstrated the effectiveness of PB203 in a pancreatic cancer animal model using humanized mice. When administered in combination with gemcitabine, a standard treatment, a strong tumor suppression effect was confirmed compared to monotherapy....In addition, PB203 showed the best tumor suppression effect in a comparative animal experiment with VEGF-A/PD-(L)1 dual-target anticancer drug candidates that are currently under active development in the global market. The results will also be disclosed through AACR."

Preclinical • Pancreatic Cancer

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development (PRNewswire) - "Chime Biologics...announced a strategic cooperation agreement with Panolos Bioscience, a South Korean biotech company to accelerate multi-specific protein development, at a signing ceremony held in Optics Valley Wuhan, Hubei Province on the 19th of September....Panolos Bioscience has entered into a collaboration with Chime Biologics for a novel multi-specific protein drug, PB203, for solid tumors (PDAC/ICC), which is in the preclinical stage with plans to conduct clinical trial Phase I in the US. Chime Biologics will provide an one-stop biologic CMC solution for the development and manufacturing of PB203 from cell line development, process development, and GMP manufacturing service."

Licensing / partnership • Oncology • Solid Tumor